Because the candeeman can!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BTO 10 BA 190418C395 @ 7.15
Oppenheimer: If WATT Can Execute, 'There Is Considerable Upside Potential'
https://www.benzinga.com/analyst-ratings/analyst-color/18/01/10994030/oppenheimer-if-energous-can-execute-there-is-considerab
WATT Insider filing on John Gaulding (added 40576 shares)
https://www.sec.gov/Archives/edgar/data/1234527/000114036118000886/xslF345X03/doc1.xml
WATT Insider filing on Martin Cooper (added 26929 shares)
https://www.sec.gov/Archives/edgar/data/1217826/000114036118000889/xslF345X03/doc1.xml
WATT Insider filing on Robert J Griffin (added 26929 shares)
https://www.sec.gov/Archives/edgar/data/1575793/000114036118000891/xslF345X03/doc1.xml
WATT Insider filing on Rex S Jackson (added 26929 shares)
https://www.sec.gov/Archives/edgar/data/1249803/000114036118000890/xslF345X03/doc1.xml
Out at 1.36, thanks
I picked up some at .99, any idea what they'll open up at?
Galectin Therapeutics' Executive Chairman to Discuss Silent Epidemic and Company's Role in Developing Treatments for NASH and Other Diseases at Robins Equity Research Roundup Conference
stock news now link
Clinical Trial To Establish Efficacy Of Gr-Md-02 In Nash Cirrhosis:
http://www.conferencecalltranscripts.org/8/summary2/?id=1982986
GALT Receives USPTO Notice of Allowance for Pectin-Derived Compound-Related Patent
http://www.streetinsider.com/dr/news.php?id=10810250
Galectin Therapeutics's buy rating reiterated at MLV & Co. $16.00 PT
http://www.dakotafinancialnews.com/mlv-co-reaffirms-buy-rating-for-galectin-therapeutics-galt/346590/
Galectin initiates enrollment in mid-stage trial of GR-MD-02 in NASH
http://m.seekingalpha.com/news/2609325-galectin-initiates-enrollment-in-mid-stage-trial-of-gr-mdminus-02-in-nash
National Marine Manufacturers Association Endorses Use of Gevo's Isobutanol in the Marine Fuel Market
http://finance.yahoo.com/news/national-marine-manufacturers-association-endorses-132000021.html
Institutional ownership up 35.47% Quarter/Quarter
http://finance.yahoo.com/q/it?s=GALT+Insider+Transactions
NRX Institutional ownership up 22.97% Quarter/Quarter
http://finance.yahoo.com/q/it?s=NRX+Insider+Transactions
NephroGenex Coverage Initiated by Analysts at MLV & Co at buy PT $20
http://www.mideasttime.com/nephrogenex-coverage-initiated-by-analysts-at-mlv-co-nrx/380676/
Galectin Therapeutics's buy rating reiterated at MLV & Co. $16.00 Price Target
http://www.analystratings.net/stocks/NASDAQ/GALT/?RegistrationCode=SocialMedia-StockTwits
Nephrogenex to Present at the Noble Financial Capital Markets Equity Conference on January 20th at 10:30am EST
http://www.businesswire.com/news/home/20150114005111/en/Nephrogenex-Present-Noble-Financial-Capital-Markets-Equity
Can't find that ticker, what is the name?
dropping after hours, somebody ask on the CC when it's going to go up
What's happening on the CC?
NAVB maybe re-test the 150dma of $3.05
Nothing flying but the birds, then again there is some movement.
That was a hard drop, don't you think buys should have been triggered?
$ADVS take over rumor
Doesn't make sense. They dish out $250M per year on divis. It is not sustainable.
I cannot see PGH beating earnings estimates this week. The divi has to be cut and should be done soon to save this disaster.
Monster Beverage Corp (MNST.O), facing investigations into the safety of its energy drinks, reported a smaller-than-expected quarterly profit as it stepped up promotional spending.
Shares in Monster, which again rejected the safety concerns as "baseless," slid 12 percent in after-hours trading even as the company reported rising sales.
The U.S. Food and Drug Administration said last month it was investigating reports of five deaths that may be related to Monster Beverage's namesake drinks.
The company is also being sued by the family of a 14-year old Maryland girl with a heart disorder who died after drinking two cans of Monster Energy drink in a 24-hour period.
As well, the company said in August that it had received a subpoena from an unnamed state attorney general related to its ingredients and advertising.
Energy drinks have come under review due to health concerns surrounding high concentrations of ingredients such as caffeine.
The earnings for the three months to September 30 predated news of the investigation and company officials did not say if they were seeing an impact on sales in the current quarter.
Monster is the top-selling energy drink in the United States but falls behind Austria's Red Bull in dollar sales. The company also sells drinks such as Java Monster and X-Press Monster.
Monster Beverage said it was not aware of a single instance in the world in which its energy drinks have caused deaths.
"There is not a shred of information which causally linked Monster to these adverse events and the lawsuit is the first the company has received alleging a fatality caused by Monster," Chief Executive Rodney Sacks said on a conference call for analysts.
Sacks added that the company should not be singled out in the case as there were many other major energy drinks on the market with comparable or higher amounts of caffeine per ounce than Monster's.
QUARTERLY PROFIT WHIMPERS
Monster's net income for the quarter ended September 30 rose to $86.1 million, or 47 cents per share, from $82.4 million or 44 cents per share, a year earlier.
But analysts on average had expected earnings of 55 cents per share, according to Thomson Reuters I/B/E/S.
Gross margin fell to 50.5 percent from 52.7 percent a year earlier, hurt by the promotional and operational costs. Promotion spending rose 23 percent.
Net sales increased 14.2 percent to $541.9 million, but this lagged analyst estimates of $578.5 million.
Sales in the quarter were partly hurt by a drop in Canada due to inventory adjustments made by distributor Coca-Cola (KO.N) Refreshments Canada, Monster said.
A stronger U.S. dollar had a negative impact of $12 million on sales and lower sales of its Monster Energy Extra Strength drink also hurt revenue, Sacks said. All other energy drinks posted higher sales, he added.
Sales of energy drinks form the fastest growing segment of the soft drinks market. Sales rose 17 percent to $9 billion in 2011 and are expected to exceed $10 billion this year, according to Beverage Digest.
Source: http://www.reuters.com/article/2012/11/08/us-monsterbeverage-results-idUSBRE8A700E20121108
Orders for U.S. durable goods rise 4.2% in July
Unreal. They were the pioneers of the smartphone.
R.I.P. RIMM
Agreed, waiting for $65.
It's an option, then again who really knows?
$65/barrel in 2013 one agency reported
Silver trade seems dead
Under $7, it's a good buy
Looks like you got your wish. Is this ETF the best that tracks the spot price in oil? Investing around this price would be a nice rate of return once oil gets back over $100/barrel.
They just reported earnings a few weeks ago, and conveniently left CDS info out. Manipulation at its finest.